The stock has a 36-month beta value of 1.26. Opinions on the stock are mixed, with 3 analysts rating it as a “buy,” 3 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for AUPH is 128.66M, and at present, short sellers hold a 5.35% of that float. On December 05, 2024, the average trading volume of AUPH was 1.23M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
AUPH) stock’s latest price update
The stock of Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) has increased by 2.47 when compared to last closing price of 8.72. Despite this, the company has experienced a 0.96% gain in its stock price over the last five trading sessions. businesswire.com reported 2024-11-18 that ROCKVILLE, Md. & EDMONTON, Alberta–(BUSINESS WIRE)–Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis.
AUPH’s Market Performance
AUPH’s stock has risen by 0.96% in the past week, with a monthly rise of 22.07% and a quarterly rise of 23.07%. The volatility ratio for the week is 3.42% while the volatility levels for the last 30 days are 4.29% for Aurinia Pharmaceuticals Inc The simple moving average for the past 20 days is 4.50% for AUPH’s stock, with a 44.95% simple moving average for the past 200 days.
Analysts’ Opinion of AUPH
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see AUPH reach a price target of $25, previously predicting the price at $34. The rating they have provided for AUPH stocks is “Overweight” according to the report published on May 05th, 2022.
Oppenheimer gave a rating of “Outperform” to AUPH, setting the target price at $31 in the report published on December 10th of the previous year.
AUPH Trading at 15.90% from the 50-Day Moving Average
After a stumble in the market that brought AUPH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -8.26% of loss for the given period.
Volatility was left at 4.29%, however, over the last 30 days, the volatility rate increased by 3.42%, as shares surge +18.68% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +23.96% upper at present.
During the last 5 trading sessions, AUPH rose by +0.85%, which changed the moving average for the period of 200-days by +55.49% in comparison to the 20-day moving average, which settled at $8.55. In addition, Aurinia Pharmaceuticals Inc saw -0.61% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AUPH starting from Bailey Jeffrey Allen, who sale 4,557 shares at the price of $8.43 back on Nov 11 ’24. After this action, Bailey Jeffrey Allen now owns 13,356 shares of Aurinia Pharmaceuticals Inc, valued at $38,416 using the latest closing price.
Smith Karen L., the Director of Aurinia Pharmaceuticals Inc, sale 5,241 shares at $8.43 during a trade that took place back on Nov 11 ’24, which means that Smith Karen L. is holding 12,672 shares at $44,182 based on the most recent closing price.
Stock Fundamentals for AUPH
Current profitability levels for the company are sitting at:
- -0.09 for the present operating margin
- 0.87 for the gross margin
The net margin for Aurinia Pharmaceuticals Inc stands at -0.1. The total capital return value is set at -0.04. Equity return is now at value -5.78, with -4.08 for asset returns.
Currently, EBITDA for the company is -63.05 million with net debt to EBITDA at 39.83. When we switch over and look at the enterprise to sales, we see a ratio of 6.04. The receivables turnover for the company is 6.04for trailing twelve months and the total asset turnover is 0.4. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.60.
Conclusion
To sum up, Aurinia Pharmaceuticals Inc (AUPH) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
